Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 2,078 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dementia Senile Clear all
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Alzheimer's Registry

NCT07420075
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Not listed
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2099
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 7, 2026, 10:47 AM EDT
Withdrawn Early Phase 1 Interventional

Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease

NCT04984330
View directory record Official record
Conditions
Amyloid, Amyloidosis, AL Amyloidosis
Interventions
Selinexor, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 7, 2026, 10:47 AM EDT
Active, not recruiting Phase 3 Interventional

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

NCT05397639
View directory record Official record
Conditions
Agitation, Alzheimer's Type Dementia
Interventions
Masupirdine 50 mg, Masupirdine 100 mg, Placebo
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
50 Years to 90 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
27
States / cities
Anaheim, California • Costa Mesa, California • Encino, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 3 Interventional

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT03393520
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
Placebo, AVP-786
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
93
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease

NCT02045056
View directory record Official record
Conditions
Preclinical Alzheimer's Disease
Interventions
Gemfibrozil, Placebo
Drug
Lead sponsor
Gregory Jicha, 323-5550
Other
Eligibility
65 Years to 90 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 7, 2026, 10:47 AM EDT
Completed No phase listed Observational

PhosphoRus, Proton Imaging and Amyloid BuRdEn (PREPARE) ON AMYLOID BURDEN AND COGNITION

NCT03999879
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Measure of OxPhos upregulation, lactate (measured with 1H-MRSI)
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
70 Years to 85 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 7, 2026, 10:47 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

ScentAware and OCT in MCI vs HC

NCT06377241
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
ScentAware, UPSIT
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

NCT02319005
View directory record Official record
Conditions
Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related, Familial Transthyretin Cardiac Amyloidosis
Interventions
Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
41
States / cities
Bakersfield, California • Beverly Hills, California • La Mesa, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Not applicable Interventional Results available

Palliative Care Educator

NCT04857060
View directory record Official record
Conditions
Advance Care Planning, Palliative Care, Alzheimer's Disease and Related Dementias, Doctor-patient Communication, Video Decision Aids
Interventions
ACP Educator led, video assisted discussion
Behavioral
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
11,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

NCT00454870
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MEM 3454
Drug
Lead sponsor
Memory Pharmaceuticals
Industry
Eligibility
50 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
7
States / cities
Phoenix, Arizona • Glendale, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2008 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment

NCT04206670
View directory record Official record
Conditions
Dementia, Mild Cognitive Impairment, Alzheimer Disease
Interventions
In-Home Technology System and Questionnaires, Waiting Control In-Home Technology System and Questionnaires
Device
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 7, 2026, 10:47 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease

NCT00299988
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Intravenous Immunoglobulin, Placebo
Drug · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers

NCT00329082
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY2062430, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
6
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2009 · Synced Oct 7, 2026, 10:47 AM EDT
Terminated Not applicable Interventional

Auricular Point Acupressure to Manage Pain in Patients With Alzheimer's Disease and Related Disorders

NCT03393546
View directory record Official record
Conditions
Pain, Alzheimer Disease
Interventions
Auricular Point Acupressure
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 7, 2026, 10:47 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Automated, Assistive, Non-Contact Sleep Quality Monitor for Individuals With Alzheimer's Disease

NCT06045988
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Sleep Disturbance
Interventions
Non-Contact Sleep Quality Monitor System
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 2 Interventional

Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen

NCT00018343
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
estrogen
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 90 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Lakewood, Washington
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 7, 2026, 10:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD

NCT03389698
View directory record Official record
Conditions
Alzheimer Disease
Interventions
GRASP Dynamic Contrast-Enhanced (DCE) MRI, 3T Brain Scan, Gadolinium-based Contrast Agent (GBCA) for MRI
Device · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
20 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 3 Interventional

Multicenter Trial of Prednisone in Alzheimer's Disease

NCT00000178
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Prednisone
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
0 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

S-Equol in Alzheimer's Disease 2 Trial

NCT03101085
View directory record Official record
Conditions
Alzheimer Disease
Interventions
S-equol and Placebo, Placebo and S-equol
Drug
Lead sponsor
Russell Swerdlow
Other
Eligibility
50 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Fairway, Kansas • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease

NCT05138848
View directory record Official record
Conditions
Alzheimer Disease, Late Onset, Mild Cognitive Impairment, Sleep, Cognitive Change, Amyloid
Interventions
Time in Bed Restriction, Sleep Schedule
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years to 85 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Not applicable Interventional Results available

STIM+: PET Biomarker Education & Disclosure

NCT04818255
View directory record Official record
Conditions
Mild Cognitive Impairment, Dementia; Alzheimer's Type (Etiology)
Interventions
PET Biomarker Disclosure
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
55 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 2 Interventional

Enhancing Quality of Life for Nursing Home Residents

NCT00388544
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Activity matched to interest, Activity matched to function, Activity matched to both interest and function
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
65 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Oct 7, 2026, 10:47 AM EDT
Terminated Phase 2 Interventional Results available

A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease

NCT01255163
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Exendin-4 SC, Placebo SC
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Not applicable Interventional Results available

Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)

NCT01609348
View directory record Official record
Conditions
Alzheimer's Disease, Depression
Interventions
Placebo, Venlafaxine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • West Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 7, 2026, 10:47 AM EDT